JP2018021051A5 - - Google Patents

Download PDF

Info

Publication number
JP2018021051A5
JP2018021051A5 JP2017160336A JP2017160336A JP2018021051A5 JP 2018021051 A5 JP2018021051 A5 JP 2018021051A5 JP 2017160336 A JP2017160336 A JP 2017160336A JP 2017160336 A JP2017160336 A JP 2017160336A JP 2018021051 A5 JP2018021051 A5 JP 2018021051A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
alkyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017160336A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018021051A (ja
JP6393380B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018021051A publication Critical patent/JP2018021051A/ja
Publication of JP2018021051A5 publication Critical patent/JP2018021051A5/ja
Application granted granted Critical
Publication of JP6393380B2 publication Critical patent/JP6393380B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017160336A 2013-11-11 2017-08-23 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2,f][1,2,4]トリアジン Active JP6393380B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361902544P 2013-11-11 2013-11-11
US61/902,544 2013-11-11

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016528882A Division JP6234571B2 (ja) 2013-11-11 2014-11-06 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2,f][1,2,4]トリアジン

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018000710A Division JP2018070658A (ja) 2013-11-11 2018-01-05 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2,f][1,2,4]トリアジン

Publications (3)

Publication Number Publication Date
JP2018021051A JP2018021051A (ja) 2018-02-08
JP2018021051A5 true JP2018021051A5 (enExample) 2018-03-22
JP6393380B2 JP6393380B2 (ja) 2018-09-19

Family

ID=52003049

Family Applications (8)

Application Number Title Priority Date Filing Date
JP2016528882A Active JP6234571B2 (ja) 2013-11-11 2014-11-06 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2,f][1,2,4]トリアジン
JP2017160336A Active JP6393380B2 (ja) 2013-11-11 2017-08-23 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2,f][1,2,4]トリアジン
JP2018000710A Withdrawn JP2018070658A (ja) 2013-11-11 2018-01-05 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2,f][1,2,4]トリアジン
JP2019222179A Active JP7054394B2 (ja) 2013-11-11 2019-12-09 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2-f][1,2,4]トリアジン
JP2020193294A Active JP7247155B2 (ja) 2013-11-11 2020-11-20 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2-f][1,2,4]トリアジン
JP2022063956A Withdrawn JP2022088661A (ja) 2013-11-11 2022-04-07 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2-f][1,2,4]トリアジン
JP2024006714A Withdrawn JP2024041986A (ja) 2013-11-11 2024-01-19 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2-f][1,2,4]トリアジン
JP2025188200A Pending JP2026027391A (ja) 2013-11-11 2025-11-07 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2-f][1,2,4]トリアジン

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016528882A Active JP6234571B2 (ja) 2013-11-11 2014-11-06 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2,f][1,2,4]トリアジン

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2018000710A Withdrawn JP2018070658A (ja) 2013-11-11 2018-01-05 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2,f][1,2,4]トリアジン
JP2019222179A Active JP7054394B2 (ja) 2013-11-11 2019-12-09 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2-f][1,2,4]トリアジン
JP2020193294A Active JP7247155B2 (ja) 2013-11-11 2020-11-20 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2-f][1,2,4]トリアジン
JP2022063956A Withdrawn JP2022088661A (ja) 2013-11-11 2022-04-07 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2-f][1,2,4]トリアジン
JP2024006714A Withdrawn JP2024041986A (ja) 2013-11-11 2024-01-19 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2-f][1,2,4]トリアジン
JP2025188200A Pending JP2026027391A (ja) 2013-11-11 2025-11-07 呼吸器合胞体ウイルス感染を処置するのに有用なピロロ[1,2-f][1,2,4]トリアジン

Country Status (36)

Country Link
US (5) US9388208B2 (enExample)
EP (3) EP3068405B1 (enExample)
JP (8) JP6234571B2 (enExample)
KR (4) KR102355881B1 (enExample)
CN (3) CN110003215B (enExample)
AP (1) AP2016009186A0 (enExample)
AU (5) AU2014346665A1 (enExample)
BR (1) BR112016010261B1 (enExample)
CA (1) CA2928674C (enExample)
CL (1) CL2016001120A1 (enExample)
CR (1) CR20160220A (enExample)
CU (1) CU20160065A7 (enExample)
CY (1) CY1121948T1 (enExample)
DK (2) DK3068405T3 (enExample)
DO (1) DOP2016000107A (enExample)
EA (2) EA029712B1 (enExample)
ES (2) ES2743619T3 (enExample)
GT (1) GT201600086A (enExample)
HR (2) HRP20191303T1 (enExample)
HU (2) HUE044960T2 (enExample)
IL (1) IL245324B (enExample)
LT (2) LT3505173T (enExample)
MD (1) MD4596C1 (enExample)
MX (2) MX376186B (enExample)
MY (2) MY182986A (enExample)
NZ (1) NZ719592A (enExample)
PE (1) PE20160670A1 (enExample)
PH (1) PH12016500867A1 (enExample)
PL (2) PL3505173T3 (enExample)
PT (2) PT3505173T (enExample)
SG (1) SG11201603427XA (enExample)
SI (2) SI3505173T1 (enExample)
TR (1) TR201910961T4 (enExample)
UA (1) UA119050C2 (enExample)
WO (1) WO2015069939A1 (enExample)
ZA (1) ZA201603123B (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI483950B (zh) 2009-09-21 2015-05-11 Gilead Sciences Inc 用於製備1’-取代碳核苷類似物之方法及中間物
PH12013500035A1 (en) 2010-07-22 2013-03-11 Gilead Sciences Inc Methods and compounds for treating paramyxoviridae virus infections
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並[3,2-d]嘧啶、呋喃並[3,2-d]嘧啶及吡咯並[3,2-d]嘧啶化合物類
MX381291B (es) 2014-09-26 2025-03-12 Riboscience Llc Derivados de nucleósidos sustituidos con 4'-vinilo como inhibidores de la replicación del arn del virus respiratorio sincitial.
TWI740546B (zh) * 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
SG10202105371YA (en) 2014-12-26 2021-07-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
SG10202109869XA (en) 2015-09-16 2021-10-28 Gilead Sciences Inc Methods for treating arenaviridae and coronaviridae virus infections
KR102185996B1 (ko) 2015-09-23 2020-12-02 머크 샤프 앤드 돔 코포레이션 4'-치환된 뉴클레오시드 리버스 트랜스크립타제 억제제 및 그의 제조법
JP6860585B2 (ja) 2016-03-09 2021-04-14 ヤンセン バイオファーマ インク. 非環状抗ウイルス 優先出願の参照による組み込み
CN110869028B (zh) * 2017-03-14 2023-01-20 吉利德科学公司 治疗猫冠状病毒感染的方法
ES2938859T3 (es) 2017-05-01 2023-04-17 Gilead Sciences Inc Una forma cristalina de (S)-2-etilbutilo 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
US11149049B2 (en) * 2017-09-18 2021-10-19 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN109748921B (zh) * 2017-11-03 2022-03-22 中国科学院上海药物研究所 N-叔丁氧羰基保护的杂环类化合物、其制备方法及其用于制备c-核苷类似物的方法
FI3706762T3 (fi) 2017-12-07 2024-12-13 Univ Emory N4-hydroksisytidiini ja johdannaisia sekä niihin liittyviä virusten vastaisia käyttötapoja
US11040975B2 (en) 2017-12-08 2021-06-22 Merck Sharp & Dohme Corp. Carbocyclic nucleoside reverse transcriptase inhibitors
CN108787177B (zh) * 2018-08-07 2024-03-15 中南大学 淤浆法制备黄原酸盐的方法及系统
US12234255B2 (en) 2019-05-14 2025-02-25 Regents Of The University Of Michigan Methods for glycosylation
CN118662520A (zh) 2020-01-27 2024-09-20 吉利德科学公司 用于治疗SARS CoV-2感染的方法
TWI874791B (zh) * 2020-02-18 2025-03-01 美商基利科學股份有限公司 抗病毒化合物
TWI884403B (zh) * 2020-02-18 2025-05-21 美商基利科學股份有限公司 抗病毒化合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
EP4106876B1 (en) * 2020-02-18 2025-09-17 Gilead Sciences, Inc. Antiviral compounds
CN111187269A (zh) * 2020-02-27 2020-05-22 江苏阿尔法药业有限公司 一种瑞德西韦中间体的合成方法
CN113336758B (zh) * 2020-03-03 2022-08-19 北京桦冠医药科技有限公司 化合物7-碘吡咯并[2,1-f][1,2,4]三嗪-4-胺的一种新合成方法
CN111233870A (zh) * 2020-03-11 2020-06-05 中国科学技术大学 用于快速制备瑞德西韦药物中间体的方法
US11613553B2 (en) 2020-03-12 2023-03-28 Gilead Sciences, Inc. Methods of preparing 1′-cyano nucleosides
EP4132651B1 (en) 2020-04-06 2026-03-18 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CN112778310B (zh) * 2020-04-20 2025-05-30 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN113527303B (zh) * 2020-04-21 2022-06-10 浙江工业大学 一种瑞德西韦母核中间体的制备工艺
CN111440176B (zh) * 2020-04-28 2022-04-26 江苏大学 金属配合物促进的瑞德西韦中间体的合成方法
ES3041698T3 (en) 2020-05-29 2025-11-13 Gilead Sciences Inc Remdesivir for the treatment of viral infections
CN111620903A (zh) * 2020-06-17 2020-09-04 安徽贝克联合制药有限公司 C-核苷类似物以及用于合成瑞德西韦合成的含腈c-核苷类化合物的制备方法及其应用
EP4172160A2 (en) 2020-06-24 2023-05-03 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
CN111732618A (zh) * 2020-07-03 2020-10-02 镇江巨杰新材料技术研发中心(有限合伙) 瑞德西韦关键片段的合成方法
CN111793101B (zh) * 2020-07-17 2022-09-30 四川大学 C-核苷化合物的合成方法
RS67481B1 (sr) 2020-08-06 2025-12-31 Richter Gedeon Nyrt Intermedijeri remdesivira
EP4200301B1 (en) 2020-08-24 2025-02-26 Gilead Sciences, Inc. Phospholipid compounds and uses thereof
HUE067491T2 (hu) 2020-08-27 2024-10-28 Gilead Sciences Inc Vegyületek és eljárások vírusfertõzések kezelésére
TWI811812B (zh) * 2020-10-16 2023-08-11 美商基利科學股份有限公司 磷脂化合物及其用途
CN112500417B (zh) * 2020-12-31 2022-01-21 山东诚汇双达药业有限公司 一种4-氨基吡咯并[2,1-f][1,2,4]三嗪的制备方法
KR102923359B1 (ko) 2021-04-16 2026-02-05 길리애드 사이언시즈, 인코포레이티드 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법
EP4387977A1 (en) * 2021-08-18 2024-06-26 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
IL310854A (en) 2021-08-20 2024-04-01 Shionogi & Co Nucleoside compounds and their drug derivatives possessing viral growth inhibitory activity
AU2023227794A1 (en) 2022-03-02 2024-10-17 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US20230382940A1 (en) * 2022-03-03 2023-11-30 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
CR20240367A (es) * 2022-03-03 2024-09-30 Gilead Sciences Inc Compuestos antivirales y métodos de elaboración y uso de los mismos.
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
WO2024173458A1 (en) 2023-02-16 2024-08-22 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
WO2025049699A1 (en) 2023-08-31 2025-03-06 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
AU2024330988A1 (en) 2023-08-31 2026-02-19 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
WO2025072641A1 (en) 2023-09-28 2025-04-03 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3565070A (en) 1969-02-28 1971-02-23 Riker Laboratories Inc Inhalation actuable aerosol dispenser
FR2224175B1 (enExample) 1973-04-04 1978-04-14 Isf Spa
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1017153B (it) 1974-07-15 1977-07-20 Isf Spa Apparecchio per inalazioni
SE438261B (sv) 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US4955371A (en) 1989-05-08 1990-09-11 Transtech Scientific, Inc. Disposable inhalation activated, aerosol device for pulmonary medicine
DE69230613T2 (de) 1991-07-02 2000-12-28 Inhale Inc Verfahren und vorrichtung zum abgeben von medikamenten in aerosolform
US5261538A (en) 1992-04-21 1993-11-16 Glaxo Inc. Aerosol testing method
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5388572A (en) 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5622163A (en) 1994-11-29 1997-04-22 Iep Group, Inc. Counter for fluid dispensers
US5544647A (en) 1994-11-29 1996-08-13 Iep Group, Inc. Metered dose inhalator
US6116234A (en) 1999-02-01 2000-09-12 Iep Pharmaceutical Devices Inc. Metered dose inhaler agitator
ATE491459T1 (de) * 2000-10-18 2011-01-15 Pharmasset Inc Modifizierte nukleoside zur behandlung von virusinfektionen und abnormaler zellulärer proliferation
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
WO2003026589A2 (en) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
AR046959A1 (es) * 2003-12-18 2006-01-04 Tibotec Pharm Ltd Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio
SG177974A1 (en) 2007-01-12 2012-02-28 Biocryst Pharm Inc Antiviral nucleoside analogs
WO2008141079A1 (en) 2007-05-10 2008-11-20 Biocryst Pharmaceuticals, Inc. Tetrahydrofuro [3 4-d] dioxolane compounds for use in the treatment of viral infections and cancer
EP2019519B1 (en) 2007-07-25 2011-07-06 Nokia Siemens Networks Oy Method for addressing ethernet streams with a structured GPON GEM Port ID
AU2009240630B2 (en) 2008-04-23 2013-07-18 Gilead Sciences, Inc. Carba-nucleoside analogs for antiviral treatment
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
BR122021021135B1 (pt) 2009-09-21 2022-08-30 Gilead Sciences, Inc Compostos análogos de 2-flúor substituído carba-nucleosídeo, composição farmacêutica e uso dos compostos análogos de 2´-flúoro substituído carbonucleosídeo
TWI483950B (zh) * 2009-09-21 2015-05-11 Gilead Sciences Inc 用於製備1’-取代碳核苷類似物之方法及中間物
TW201201815A (en) * 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
WO2012012465A1 (en) 2010-07-19 2012-01-26 Clarke, Michael, O'neil Hanrahan Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
PH12013500035A1 (en) * 2010-07-22 2013-03-11 Gilead Sciences Inc Methods and compounds for treating paramyxoviridae virus infections
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之2’-氟取代之碳-核苷類似物
WO2012039791A1 (en) * 2010-09-20 2012-03-29 Gilead Sciences, Inc. 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
WO2012087596A1 (en) 2010-12-20 2012-06-28 Gilead Sciences, Inc. Combinations for treating hcv
US9156872B2 (en) 2011-04-13 2015-10-13 Merck Sharp & Dohme Corp. 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US20130143835A1 (en) * 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
SG10201610936RA (en) * 2011-12-22 2017-02-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
AU2013232378B2 (en) 2012-03-13 2017-09-28 Gilead Sciences, Inc. 2'- substituted carba-nucleoside analogs for antiviral treatment
CN111848711A (zh) 2012-10-08 2020-10-30 埃迪尼克斯医药有限责任公司 用于hcv感染的2′-氯核苷类似物
TWI582077B (zh) 2013-11-07 2017-05-11 必治妥美雅史谷比公司 作爲IL-12、IL-23及/或IFNα反應調節劑之經烷基-醯胺取代之吡啶化合物
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ

Similar Documents

Publication Publication Date Title
JP2018021051A5 (enExample)
JP2017523169A5 (enExample)
JP2015024998A5 (enExample)
JP2016536286A5 (enExample)
JP2018537535A5 (enExample)
JP2019505529A5 (enExample)
JP2006182786A5 (enExample)
JP2016527217A5 (enExample)
JP2016525102A5 (enExample)
JP2018524298A5 (enExample)
JP2012504133A5 (enExample)
JP2013534248A5 (enExample)
JP2016515561A5 (enExample)
JP2020507589A5 (enExample)
JP2019516739A5 (enExample)
JP2014500861A5 (enExample)
JP2013542261A5 (enExample)
JP2009535352A5 (enExample)
JP2013508279A5 (enExample)
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
JP2016522254A5 (enExample)
JP2020097577A5 (enExample)
JP2014505107A5 (enExample)
JP2017533930A5 (enExample)
JP2019535723A5 (enExample)